Femasys is trading at $2.79 (+8.81%) in after-hours trading amid Minnesota Women’s Care’s announcement that it will implement FemVue and FemaSeed Complete across all four locations.

  • The adoption expands commercial deployment of Femasys’s fertility portfolio.
  • The announcement was made on September 15, 2026.
  • Regular-session shares declined 4.12% to $2.56; the release did not explicitly link the announcement to the after-hours gain.